Mirtazapine Explained

Verifiedfields:verified
Watchedfields:verified
Verifiedrevid:408610027
Width:175
Width2:175
Tradename:Remeron, Mirataz, Avanza, others
Dailymedid:Mirtazapine
Pregnancy Au:B3
Pregnancy Au Comment:[1]
Routes Of Administration:By mouth (tablets), topical
Class:Noradrenergic and specific serotonergic antidepressant (NaSSA)
Atc Prefix:N06
Atc Suffix:AX11
Legal Au:S4
Legal Br:C1
Legal Br Comment:[2]
Legal Ca:Rx-only
Legal Uk:POM
Legal Us:Rx-only
Legal Eu:Rx-only
Bioavailability:50%
Protein Bound:85%[3]
Metabolism:Liver (CYP1A2, CYP2D6, CYP3A4)
Metabolites:Desmethylmirtazapine (contributes 3–10% of activity)[4]
Elimination Half-Life:20–40 hours
Excretion:Urine

75%
Feces: 15%

Iuphar Ligand:7241
Cas Number:85650-52-8
Pubchem:4205
Drugbank:DB00370
Chemspiderid:4060
Unii:A051Q2099Q
Kegg:D00563
Chebi:6950
Chembl:654
Synonyms:Mepirzapine; 6-Azamianserin; ORG-3770
Iupac Name:(±)-5-methyl-2,5,19-triazatetracyclo[13.4.0.02,7.08,13]nonadeca-1(15),8,10,12,16,18-hexaene
C:17
H:19
N:3
Smiles:n1cccc3c1N4C(c2ccccc2C3)CN(C)CC4
Stdinchi:1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3
Stdinchikey:RONZAEMNMFQXRA-UHFFFAOYSA-N
Chirality:Racemic mixture
Density:1.22
Melting Point:114
Melting High:116
Boiling Point:432
Solubility:Soluble in methanol and chloroform

Mirtazapine, sold under the brand name Remeron among others, is an atypical tetracyclic antidepressant, and as such is used primarily to treat depression.[5] Its effects may take up to four weeks but can also manifest as early as one to two weeks.[5] It is often used in cases of depression complicated by anxiety or insomnia.[6] The effectiveness of mirtazapine is comparable to other commonly prescribed antidepressants.[7] It is taken by mouth.[5]

Common side effects include sleepiness, dizziness, increased appetite and weight gain.[5] Serious side effects may include mania, low white blood cell count, and increased suicide among children.[5] Withdrawal symptoms may occur with stopping.[8] It is not recommended together with a monoamine oxidase inhibitor, although evidence supporting the danger of this combination has been challenged. It is unclear if use during pregnancy is safe. How it works is not clear, but it may involve blocking certain adrenergic and serotonin receptors.[5] Chemically, it is a tetracyclic antidepressant,[5] and is closely related to mianserin. It also has strong antihistaminergic effects.[9] [5]

Mirtazapine came into medical use in the United States in 1996.[5] The patent expired in 2004, and generic versions are available.[5] [10] In 2021, it was the 124th most commonly prescribed medication in the United States, with more than fourmillion prescriptions.[11] [12]

Medical uses

Mirtazapine is approved by the United States Food and Drug Administration for the treatment of major depressive disorder in adults.[13]

Depression

Mirtazapine is primarily used for major depressive disorder and other mood disorders.[14] [15] Onset of action appears faster than some selective serotonin reuptake inhibitors and similar to tricyclic antidepressants.

In 2010, the National Institute for Health and Care Excellence recommended generic selective serotonin reuptake inhibitors as first line choices, as they are "equally effective as other antidepressants and have a favourable risk–benefit ratio."[16] With respect to mirtazapine, it found: "There is no difference between mirtazapine and other antidepressants on any efficacy measure, although in terms of achieving remission mirtazapine appears to have a statistical though not clinical advantage. In addition, mirtazapine has a statistical advantage over selective serotonin reuptake inhibitors in terms of reducing symptoms of depression, but the difference is not clinically significant. However, there is strong evidence that patients taking mirtazapine are less likely to leave treatment early because of side effects, although this is not the case for patients reporting side effects or leaving treatment early for any reason."[17]

A 2011 Cochrane review that compared mirtazapine to other antidepressants found that, while it appears to have a faster onset in people for whom it works (measured at two weeks), its efficacy is about the same as other antidepressants after six weeks' use.[18]

A 2012 review focused on antidepressants and sleep found that in many people with sleep disorders caused by depression, mirtazapine reduces the time it takes to fall asleep and increases the quality of sleep, but that in some people it can disturb sleep, especially at higher doses, causing restless leg syndrome in 8 to 28% of people and in rare cases causes REM sleep behavior disorder.[19] This seemingly paradoxical dose–response curve of mirtazapine with respect to somnolence is owed to the exceptionally high affinity of the drug for the histamine H1, 5-HT2A, and 5-HT2C receptors; exhibiting near exclusive occupation of these receptors at doses ≤15 mg. However, at higher doses, inverse agonism and constitutive activation of the α2A-, α2B-, and α2C-adrenergic receptors begins to offset activity at H1 receptors leading to decreased somnolence and even a subjective sensation of "activation" in treated patients.[20]

A 2018 analysis of 21 antidepressants found them to be fairly similar overall. It found tentative evidence for mirtazapine being in the more effective group and middle in tolerability.[21]

After one week of usage, mirtazapine was found to have an earlier onset of action compared to selective serotonin reuptake inhibitors.[22] [23]

Other

There is also some evidence supporting its use in treating the following conditions, for which it is sometimes prescribed off-label:

Side effects

A 2011 Cochrane review found that, compared with other antidepressants, it is more likely to cause weight gain and sleepiness, but it is less likely to cause tremor than tricyclic antidepressants, and less likely to cause nausea and sexual dysfunction than selective serotonin reuptake inhibitors.[18]

Very common (≥10% incidence) adverse effects include constipation, dry mouth, sleepiness, increased appetite (17%) and weight gain (>7% increase in <50% of children).[3] [38] [39] [40] [41] [42] [43] [44] [45]

Common (1–10% incidence) adverse effects include weakness, confusion, dizziness, fasciculations (muscle twitches), peripheral edema (swelling, usually of the lower limbs), and negative lab results like elevated transaminases, elevated serum triglycerides, and elevated total cholesterol.[39]

Mirtazapine is not considered to have a risk of many of the side effects often associated with other antidepressants like the selective serotonin reuptake inhibitors, and may actually improve certain ones when taken in conjunction with them.[9] (Those adverse effects include decreased appetite, weight loss, insomnia, nausea and vomiting, diarrhea, urinary retention, increased body temperature, excessive sweating, pupil dilation and sexual dysfunction.[9])

In general, some antidepressants, especially selective serotonin reuptake inhibitors, can paradoxically exacerbate some peoples' depression or anxiety or cause suicidal ideation.[46] Despite its sedating action, mirtazapine is also believed to be capable of this, so in the United States and certain other countries, it carries a black box label warning of these potential effects, especially for people under the age of 25.

Mirtazapine may induce arthralgia (non-inflammatory joint pain).[47]

A case report published in 2000 noted an instance in which mirtazapine counteracted the action of clonidine, causing a dangerous rise in blood pressure.[48]

In a study comparing 32 antidepressants of all pharmacological classes, mirtazapine was one of the antidepressants most likely to cause nightmare disorder, sleepwalking, restless legs syndrome, night terrors and sleep paralysis.[49]

Mirtazapine has been associated with an increased risk of death compared to other antidepressants in several studies. However, it is more likely that the residual differences between people prescribed mirtazapine rather than a selective serotonin reuptake inhibitor account for the difference in risk of mortality.[50]

Withdrawal

Mirtazapine and other antidepressants may cause withdrawal symptoms upon cessation.[9] [51] A gradual and slow reduction in dose is recommended to minimize withdrawal symptoms.[52] Effects of sudden cessation of treatment with mirtazapine may include depression, anxiety, tinnitus, panic attacks, vertigo, restlessness, irritability, decreased appetite, insomnia, diarrhea, nausea, vomiting, flu-like symptoms, allergy-like symptoms such as pruritus, headaches, and sometimes mania or hypomania.[53] [54] [55]

Overdose

Mirtazapine is considered to be relatively safe in the event of an overdose,[23] although it is considered slightly more toxic in overdose than most of the selective serotonin reuptake inhibitors (except citalopram).[56] Unlike the tricyclic antidepressants, mirtazapine showed no significant cardiovascular adverse effects at 7 to 22 times the maximum recommended dose.

Twelve reported fatalities have been attributed to mirtazapine overdose.[57] [58] The fatal toxicity index (deaths per million prescriptions) for mirtazapine is 3.1 (95% CI: 0.1 to 17.2). This is similar to that observed with selective serotonin reuptake inhibitors.[59]

Interactions

Concurrent use with inhibitors or inducers of the cytochrome P450 isoenzymes CYP1A2, CYP2D6, and/or CYP3A4 can result in altered concentrations of mirtazapine, as these are the main enzymes responsible for its metabolism. As examples, fluoxetine and paroxetine, inhibitors of these enzymes, are known to modestly increase mirtazapine levels, while carbamazepine, an inducer, considerably decreases them.[4] Liver impairment and moderate chronic kidney disease have been reported to decrease the oral clearance of mirtazapine by about 30%; severe kidney disease decreases it by 50%.[4]

Mirtazapine in combination with a selective serotonin reuptake inhibitor, serotonin–norepinephrine reuptake inhibitor, or tricyclic antidepressant as an augmentation strategy is considered to be relatively safe and is often employed therapeutically but caution should be given when combined with fluvoxamine. There is a combination of venlafaxine and mirtazapine, sometimes referred to as "California rocket fuel".[60] [61] Several case reports document serotonin syndrome induced by the combination of mirtazapine with other agents (olanzapine,[62] quetiapine,[63] tramadol and venlafaxine[64]). Adding fluvoxamine to treatment with mirtazapine may cause a significant increase in mirtazapine concentration. This interaction may necessitate adjustment of the mirtazapine dosage.[65] [66]

According to information from the manufacturers, mirtazapine should not be started within two weeks of any monoamine oxidase inhibitor usage; likewise, monoamine oxidase inhibitors should not be administered within two weeks of discontinuing mirtazapine.

The addition of mirtazapine to a monoamine oxidase inhibitor, while potentially having typical or idiosyncratic (unique to the individual) reactions not herein described, does not appear to cause serotonin syndrome. This is in accordance with the fact that the 5-HT2A receptor is the predominant serotonin receptor thought to be involved in the pathophysiology of serotonin syndrome (with the 5-HT1A receptor seeming to be protective). Mirtazapine is a potent 5-HT2A receptor antagonist, and cyproheptadine, a medication that shares this property, mediates recovery from serotonin syndrome and is an antidote against it.[67]

There is a possible interaction that results in a hypertensive crisis when mirtazapine is given to a patient that has already been on steady doses of clonidine. This involves a subtle consideration, when patients have been on chronic therapy with clonidine and suddenly stop the dosing, a rapid hypertensive rebound sometimes (20%) occurs from increased sympathetic outflow. Clonidine's blood pressure lowering effects are due to stimulation of presynaptic α2 autoreceptors in the CNS which suppress sympathetic outflow. Mirtazapine itself blocks these same α2 autoreceptors, so the effect of adding mirtazapine to a patient stabilized on clonidine may precipitate withdrawal symptoms.[68]

Pharmacology

Pharmacodynamics

See also: Pharmacology of antidepressants.

Mirtazapine[69]
data-sort-type=number !Ki (nM) Species Ref
10000+ Human [70]
4600+ Human
10000+ Human
data-sort-value=3330 3330–5010 Human
data-sort-value=3534 3534–12600 Human
794–5,010 Human
728 Human
583 Human
data-sort-value=6 6.3–69Human
200Human
data-sort-value=8 8.9–39Human
5-HT38.1Human[71]
10000+ Human
670 Human
265Human
1815Human
20Human
88Human
18Human
10000+ Human
data-sort-value=4167 4167 Rat
5454+ Human
data-sort-value=5723 5,723 Human
data-sort-value=2518 2,518 Human
0.14–1.6Human[72] [73]
10000+ Rat [74]
data-sort-value=83200 83200 Human
100000+ Human
670 Human [75]
data-sort-value=6905 6905 Rat
10000+ Rat
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site.

Mirtazapine is sometimes described as a noradrenergic and specific serotonergic antidepressant (NaSSA), although the actual evidence in support of this label has been regarded as poor. It is a tetracyclic piperazine-azepine.[76]

Mirtazapine has antihistamine, α2-blocker, and antiserotonergic activity.[77] It is specifically a potent antagonist or inverse agonist of the α2A-, α2B-, and α2C-adrenergic receptors, the serotonin 5-HT2A, 5-HT2C, and the histamine H1 receptor. Unlike many other antidepressants, it does not inhibit the reuptake of serotonin, norepinephrine, or dopamine, nor does it inhibit monoamine oxidase.[78] Similarly, mirtazapine has weak or no activity as an anticholinergic or blocker of sodium or calcium channels, in contrast to most tricyclic antidepressants. In accordance, it has better tolerability and low toxicity in overdose.[79] As an H1 receptor antagonist, mirtazapine is extremely potent, and is in fact one of the most potent H1 receptor inverse agonists among tricyclic and tetracyclic antidepressants and most antihistamines in general.[80] [81] Antagonism of the H1 receptor is by far the strongest activity of mirtazapine, with the drug acting as a selective H1 receptor antagonist at low concentrations.

The (S)-(+) enantiomer of mirtazapine is responsible for antagonism of the serotonin 5-HT2A and 5-HT2C receptors, while the (R)-(–) enantiomer is responsible for antagonism of the 5-HT3 receptor.[82] Both enantiomers are involved in antagonism of the H1 and α2-adrenergic receptors,[38] [82] although the (S)-(+) enantiomer is the stronger antihistamine.

Although not clinically relevant, mirtazapine has been found to act as a partial agonist of the κ-opioid receptor at high concentrations (EC50 = 7.2 μM).[83]

α2-Adrenergic receptor

Antagonism of the α2-adrenergic receptors, which function largely as inhibitory autoreceptors and heteroreceptors, enhances adrenergic and serotonergic neurotransmission, notably central 5-HT1A receptor mediated transmission in the dorsal raphe nucleus and hippocampus; hence, mirtazapine's classification as a NaSSA. Indirect α1 adrenoceptor-mediated enhancement of serotonin cell firing and direct blockade of inhibitory α2 heteroreceptors located on serotonin terminals are held responsible for the increase in extracellular serotonin.[9] [14] [84] [85] [86] Because of this, mirtazapine has been said to be a functional "indirect agonist" of the 5-HT1A receptor.[85] Increased activation of the central 5-HT1A receptor is thought to be a major mediator of efficacy of most antidepressant drugs.[87]

5-HT2 receptor

Antagonism of the 5-HT2 subfamily of receptors and inverse agonism of the 5-HT2C receptor appears to be in part responsible for mirtazapine's efficacy in the treatment of depressive states.[88] [89] Mirtazapine increases dopamine release in the prefrontal cortex.[90] Accordingly, it was shown that by blocking the α2-adrenergic receptors and 5-HT2C receptors mirtazapine disinhibited dopamine and norepinephrine activity in these areas in rats.[91] In addition, mirtazapine's antagonism of 5-HT2A receptors has beneficial effects on anxiety, sleep and appetite, as well as sexual function regarding the latter receptor.[9] [92] Mirtazapine has been shown to lower drug seeking behaviour (more specifically to methamphetamine) in various human and animal studies.[93] [94] [95] It is also being investigated in substance abuse disorders to reduce withdrawal effects and improve remission rates.[93] [96] [97] [98]

Mirtazapine significantly improves pre-existing symptoms of nausea, vomiting, diarrhea, and irritable bowel syndrome in affected individuals.[99] Mirtazapine may be used as an inexpensive antiemetic alternative to Ondansetron.[33] In conjunction with substance abuse counseling, mirtazapine has been investigated for the purpose of reducing methamphetamine use in dependent individuals with success. In contrast to mirtazapine, the selective serotonin reuptake inhibitors, serotonin–norepinephrine reuptake inhibitors, monoamine oxidase inhibitors, and some tricyclic antidepressants increase the general activity of the 5-HT2A, 5-HT2C, and 5-HT3 receptors leading to a number of negative changes and side effects, the most prominent of which including anorexia, insomnia, nausea, and diarrhea, among others. Its reduced incidence of sexual dysfunction (such as loss of libido and anorgasmia) could be a product of negligible binding to the serotonin transporter (as is generally the cause of sexual dysfunction with most selective serotonin reuptake inhibitors) and antagonism of the 5-HT2A receptors; however, Mirtazapine's high affinity towards and inverse agonism of the 5-HT2C receptors may greatly attenuate those pro-sexual factors (as evidenced by the pro-sexual effects of drugs like m-CPP and lorcaserin which agonize 5-HT2C receptors in a reasonably selective manner). As a result, it is often combined with these drugs to reduce their side-effect profile and to produce a stronger antidepressant effect.[92] [100]

Mirtazapine does not have pro-serotonergic activity and thus does not cause serotonin syndrome.[101] [102] This is in accordance with the fact that it is not a serotonin reuptake inhibitor or monoamine oxidase inhibitor, nor a serotonin receptor agonist. There are no reports of serotonin syndrome in association with mirtazapine alone, and mirtazapine has not been found to cause serotonin syndrome in overdose.[103] However, there are a handful of case reports of serotonin syndrome occurring with mirtazapine in combination with serotonergic drugs like selective serotonin reuptake inhibitors, although such reports are very rare, and do not necessarily implicate mirtazapine as causative.[104] [105] [106]

5-HT3 receptor

It is a potent 5-HT3 blocker. It may relieve chemotherapy-related and advanced cancer-related nausea.[33]

H1 receptor

Mirtazapine is a very strong H1 receptor antagonist and, as a result, it can cause powerful sedative and hypnotic effects. A single 15 mg dose of mirtazapine to healthy volunteers has been found to result in over 80% occupancy of the H1 receptor and to induce intense sleepiness.[107] After a short period of chronic treatment, however, the H1 receptor tends to sensitize and the antihistamine effects become more tolerable. Many patients may also dose at night to avoid the effects, and this appears to be an effective strategy for combating them. Blockade of the H1 receptor may improve pre-existing allergies, pruritus, nausea, and insomnia in affected individuals. It may also contribute to weight gain, however. In contrast to the H1 receptor, mirtazapine has only low affinity for the muscarinic acetylcholine receptors, although anticholinergic side effects like dry mouth, constipation, and mydriasis are still sometimes seen in clinical practice.[108]

Pharmacokinetics

The oral bioavailability of mirtazapine is about 50%. It is found mostly bound to plasma proteins, about 85%. It is metabolized primarily in the liver by N-demethylation and hydroxylation via cytochrome P450 enzymes, CYP1A2, CYP2D6, CYP3A4.[109] [71] The overall elimination half-life is 20–40 hours, and this is independent of dosage.[4] It is conjugated in the kidney for excretion in the urine, where 75% of the drug is excreted,[110] and about 15% is eliminated in feces. Desmethylmirtazapine is an active metabolite of mirtazapine which is believed to contribute about 3-10% to the drugs overall effects and has a half-life of about 25 hours.[4]

Chemistry

Mirtazapine is a tetracyclic piperazinoazepine; mianserin was developed by the same team of organic chemists and mirtazapine differs from it via addition of a nitrogen atom in one of the rings.[111] [112] It is a racemic mixture of enantiomers. The (S)-(+)-enantiomer is known as esmirtazapine.

Analogues of mirtazapine include mianserin, setiptiline, and aptazapine.

Synthesis

A chemical synthesis of mirtazapine has been published. The first step of synthesis is a condensation reaction between the molecule 2-chloro 3-cyanopyridine and the molecule 1-methyl-3-phenylpiperazine.[113]

History

Mirtazapine was first synthesized at Organon and published in 1989, was first approved for use in major depressive disorder in the Netherlands in 1994, and was introduced in the United States in 1996 under the brand name Remeron.[114] [115] [116]

Society and culture

Generic names

Mirtazapine is the English and French generic name of the drug and its,,,,, and .[117] [118] [119] Its generic name in Spanish, Italian, and Portuguese is mirtazapina and in German, Turkish and Swedish is mirtazapin.

Brand names

Mirtazapine is marketed under many brand names worldwide, including Adco-Mirteron, Afloyan, Amirel, Arintapin Smelt, Avanza, Axit, Azapin, Beron, Bilanz, Blumirtax, Calixta, Ciblex, Combar, Comenter, Depreram, Divaril, Esprital, Maz, Menelat, Mepirzapine, Merdaten, Meronin, Mi Er Ning, Milivin, Minelza, Minivane, Mirastad, Mirazep, Miro, Miron, Mirrador, Mirt, Mirta, Mirtabene, Mirtadepi, Mirtagamma, Mirtagen, Mirtalan, Mirtamor, Mirtamylan, Mirtan, Mirtaneo, Mirtanza, Mirtapax, Mirtapil, Mirtapine, Mirtaron, Mirtastad, Mirtax, Mirtaz, Mirtazap, Mirtazapin, Mirtazapina, Mirtazapine, Mirtazapinum, Mirtazelon, Mirtazon, Mirtazonal, Mirtel, Mirtimash, Mirtin, Mirtine, Mirtor, Mirzapine, Mirzaten, Mirzest, Mitaprex, Mitaxind, Mitocent, Mitrazin, Mizapin, Motofen, Mytra, Norset, Noxibel, Pharmataz, Promyrtil, Rapizapine, Ramure, Razapina, Redepra, Reflex, Remergil, Remergon, Remeron, Remirta, Rexer, Saxib, Sinmaron, Smilon, Tazepin, Tazimed, Tetrazic, Tifona, U-Mirtaron, U-zepine, Valdren, Vastat, Velorin, Yarocen, Zania, Zapex, Zestat, Zismirt, Zispin, Zuleptan, and Zulin.

Research

The use of mirtazapine has been explored in several additional conditions:

Veterinary use

Mirtazapine also has some veterinary use in cats and dogs. Mirtazapine is sometimes prescribed as an appetite stimulant for cats or dogs experiencing loss of appetite due to medical conditions such as chronic kidney disease. It is especially useful for treating combined poor appetite and nausea in cats and dogs.[131] [132]

Mirtazapine is indicated for bodyweight gain in cats experiencing poor appetite and weight loss resulting from chronic medical conditions.[133] [134]

There are two options for administration: tablets given orally, and an ointment applied topically to the inner surface of the ear.

The most common side effects include signs of local irritation or inflammation at the site where the ointment is applied and behavioural changes (increased meowing, hyperactivity, disoriented state or inability to co-ordinate muscle movements, lack of energy/weakness, attention-seeking, and aggression).

Notes and References

  1. Web site: Mirtazapine Use During Pregnancy . Drugs.com . 23 September 2019 . 4 March 2020 . 22 August 2020 . https://web.archive.org/web/20200822200226/https://www.drugs.com/pregnancy/mirtazapine.html . live .
  2. Web site: Anvisa . Brazilian Health Regulatory Agency . 31 March 2023 . RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial . Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control. live . https://web.archive.org/web/20230803143925/https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992 . 3 August 2023 . 16 August 2023 . . pt-BR . 4 April 2023.
  3. Web site: REMERON (mirtazapine) tablet, film coated [Organon Pharmaceuticals USA] ]. DailyMed . Organon Pharmaceuticals USA . October 2012 . 24 October 2013 . 10 January 2021 . https://web.archive.org/web/20210110090359/https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=010f9162-9f7f-4b6d-a6e4-4f832f26f38e . live .
  4. Timmer CJ, Sitsen JM, Delbressine LP . Clinical pharmacokinetics of mirtazapine . Clinical Pharmacokinetics . 38 . 6 . 461–474 . June 2000 . 10885584 . 10.2165/00003088-200038060-00001 . 27697181 .
  5. Web site: Mirtazapine Monograph for Professionals . Drugs.com . American Society of Health-System Pharmacists . 20 November 2018 . 10 January 2021 . https://web.archive.org/web/20210110231757/https://www.drugs.com/monograph/mirtazapine.html . live .
  6. Nutt DJ . Tolerability and safety aspects of mirtazapine . Human Psychopharmacology . 17 . Suppl 1 . S37–S41 . June 2002 . 12404669 . 10.1002/hup.388 . 23699759 .
  7. Web site: [129] Mirtazapine: Update on efficacy, safety, dose response ]. www.ti.ubc.ca . 8 May 2021 . 7 May 2021 . https://web.archive.org/web/20210507191909/https://www.ti.ubc.ca/2021/05/06/129-mirtazapine-update-on-efficacy-safety-dose-response/ . live .
  8. Book: British national formulary : BNF 74. 2017. British Medical Association. 978-0857112989. 354. 74.
  9. Anttila SA, Leinonen EV . A review of the pharmacological and clinical profile of mirtazapine . CNS Drug Reviews . 7 . 3 . 249–264 . 2001 . 11607047 . 6494141 . 10.1111/j.1527-3458.2001.tb00198.x .
  10. Book: Schatzberg AF, Cole JO, DeBattista C . Manual of Clinical Psychopharmacology . 7th . 2010. American Psychiatric Publishing . Arlington, VA . 978-1-58562-377-8 . 3 .
  11. Web site: The Top 300 of 2021 . ClinCalc . 14 January 2024 . 15 January 2024 . https://web.archive.org/web/20240115223848/https://clincalc.com/DrugStats/Top300Drugs.aspx . live .
  12. Web site: Mirtazapine - Drug Usage Statistics . ClinCalc . 14 January 2024 . 20 October 2020 . https://web.archive.org/web/20201020055609/https://clincalc.com/DrugStats/Drugs/Mirtazapine . live .
  13. Book: Jilani TN, Gibbons JR, Faizy RM, Saadabadi A . Mirtazapine . 2022 . http://www.ncbi.nlm.nih.gov/books/NBK519059/ . StatPearls . Treasure Island (FL) . StatPearls Publishing . 30085601 . 5 December 2022 . 12 December 2022 . https://web.archive.org/web/20221212213412/https://www.ncbi.nlm.nih.gov/books/NBK519059/ . live .
  14. Gorman JM . Mirtazapine: clinical overview . The Journal of Clinical Psychiatry . 60 . Suppl 17 . 9–13; discussion 46–8 . 1999 . 10446735 .
  15. Benjamin S, Doraiswamy PM . Review of the use of mirtazapine in the treatment of depression . Expert Opinion on Pharmacotherapy . 12 . 10 . 1623–1632 . July 2011 . 21644844 . 10.1517/14656566.2011.585459 . 10212539 .
  16. Book: Pharmacological Interventions: 10.14. Clinical Practice Recommendations. Pharmacological Interventions. 2010. National Collaborating Centre for Mental Health/British Psychological Society. 22 July 2017. 6 September 2020. https://web.archive.org/web/20200906074156/https://www.ncbi.nlm.nih.gov/books/NBK63751/#ch10.s159. live.
  17. Book: Pharmacological Interventions: Third-Generation Antidepressants: 10.8.3. Mirtazapine. Pharmacological Interventions. 2010. National Collaborating Centre for Mental Health/British Psychological Society. 22 July 2017. 6 September 2020. https://web.archive.org/web/20200906074156/https://www.ncbi.nlm.nih.gov/books/NBK63751/#ch10.s68. live.
  18. Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA . Mirtazapine versus other antidepressive agents for depression . The Cochrane Database of Systematic Reviews . 12 . CD006528 . December 2011 . 22161405 . 4158430 . 10.1002/14651858.CD006528.pub2 .
  19. Wichniak A, Wierzbicka A, Jernajczyk W . Sleep and antidepressant treatment . Current Pharmaceutical Design . 18 . 36 . 5802–5817 . 2012 . 22681161 . 10.2174/138161212803523608 .
  20. Leonard S. 2015. Dose-Dependent Sedating and Stimulating Effects of Mirtazapine. Proceedings of UCLA Healthcare. 19. 27 August 2021. 23 September 2021. https://web.archive.org/web/20210923115736/https://www.proceedings.med.ucla.edu/wp-content/uploads/2016/11/Dose-Dependent-Sedating-and-Stimulating-Effects-of-Mirtazapine.pdf. live.
  21. Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JP, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JP, Geddes JR . 6 . Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis . Lancet . 391 . 10128 . 1357–1366 . April 2018 . 29477251 . 5889788 . 10.1016/S0140-6736(17)32802-7 .
  22. Thompson C . Onset of action of antidepressants: results of different analyses . Human Psychopharmacology . 17 . Suppl 1 . S27–S32 . June 2002 . 12404667 . 10.1002/hup.386 . 45925573 . free .
  23. Book: 978-0-47-097948-8 . Maudsley Prescribing Guidelines in Psychiatry . 11th . Taylor D, Paton C, Shitij K . 2012 . Wiley-Blackwell . West Sussex .
  24. Goodnick PJ, Puig A, DeVane CL, Freund BV . Mirtazapine in major depression with comorbid generalized anxiety disorder . The Journal of Clinical Psychiatry . 60 . 7 . 446–448 . July 1999 . 10453798 . 10.4088/JCP.v60n0705 .
  25. Rifkin-Zybutz R, MacNeill S, Davies SJ, Dickens C, Campbell J, Anderson IM, Chew-Graham CA, Peters TJ, Lewis G, Wiles N, Kessler D . 6 . Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial . Journal of Psychopharmacology . 34 . 12 . 1342–1349 . December 2020 . 33143538 . 7708671 . 10.1177/0269881120965939 . free .
  26. Croom KF, Perry CM, Plosker GL . Mirtazapine: a review of its use in major depression and other psychiatric disorders . CNS Drugs . 23 . 5 . 427–452 . 2009 . 19453203 . 10.2165/00023210-200923050-00006 . 41694941 .
  27. Landowski J . [Mirtazapine--an antidepressant] . pl . Psychiatria Polska . 36 . 6 Suppl . 125–130 . 2002 . 12647431 .
  28. Chinuck RS, Fortnum H, Baldwin DR . Appetite stimulants in cystic fibrosis: a systematic review . Journal of Human Nutrition and Dietetics . 20 . 6 . 526–537 . December 2007 . 18001374 . 10.1111/j.1365-277X.2007.00824.x . 22500622 .
  29. Davis MP, Khawam E, Pozuelo L, Lagman R . Management of symptoms associated with advanced cancer: olanzapine and mirtazapine. A World Health Organization project . Expert Review of Anticancer Therapy . 2 . 4 . 365–376 . August 2002 . 12647979 . 10.1586/14737140.2.4.365 . 72195061 .
  30. Clark MS, Smith PO, Jamieson B . FPIN's clinical inquiries: Antidepressants for the treatment of insomnia in patients with depression . American Family Physician . 84 . 9 . 1–2 . November 2011 . 22164891 . 11 July 2017 . 9 July 2020 . https://web.archive.org/web/20200709135601/https://www.aafp.org/afp/2011/1101/od1.pdf . live .
  31. The Effects of Antidepressants on Sleep. Psychiatric Times. 13 June 2012. 11 July 2017. Winokur A, Demartinis N. 29. 6. 10 June 2020. https://web.archive.org/web/20200610174804/https://www.psychiatrictimes.com/sleep-disorders/effects-antidepressants-sleep. dead.
  32. Li TC, Shiah IS, Sun CJ, Tzang RF, Huang KC, Lee WK . Mirtazapine relieves post-electroconvulsive therapy headaches and nausea: a case series and review of the literature . The Journal of ECT . 27 . 2 . 165–167 . June 2011 . 21602639 . 10.1097/YCT.0b013e3181e63346 .
  33. Kast RE, Foley KF . Cancer chemotherapy and cachexia: mirtazapine and olanzapine are 5-HT3 antagonists with good antinausea effects . European Journal of Cancer Care . 16 . 4 . 351–354 . July 2007 . 17587360 . 10.1111/j.1365-2354.2006.00760.x .
  34. Twycross R, Greaves MW, Handwerker H, Jones EA, Libretto SE, Szepietowski JC, Zylicz Z . Itch: scratching more than the surface . QJM . 96 . 1 . 7–26 . January 2003 . 12509645 . 10.1093/qjmed/hcg002 . free .
  35. Greaves MW . Itch in systemic disease: therapeutic options . Dermatologic Therapy . 18 . 4 . 323–327 . 2005 . 16297004 . 10.1111/j.1529-8019.2005.00036.x . 3210356 . free .
  36. Colombo B, Annovazzi PO, Comi G . Therapy of primary headaches: the role of antidepressants . Neurological Sciences . 25 . Suppl 3 . S171–S175 . October 2004 . 15549531 . 10.1007/s10072-004-0280-x . 21285843 .
  37. Tajti J, Almási J . [Effects of mirtazapine in patients with chronic tension-type headache. Literature review] . hu . Neuropsychopharmacologia Hungarica . 8 . 2 . 67–72 . June 2006 . 17073214 .
  38. Web site: Axit Mirtazapine PRODUCT INFORMATION. TGA eBusiness Services. alphapharm. 15 October 2013. 25 October 2011. 20 September 2020. https://web.archive.org/web/20200920021431/https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-05345-3. live.
  39. Web site: Mirtazapine 30 mg Tablets – Summary of Product Characteristics. 20 March 2013. 24 October 2013. PDF. electronic Medicines Compendium. Sandoz Limited. https://web.archive.org/web/20170731104144/http://www.medicines.org.uk/emc/medicine/25201/SPC/Mirtazapine+30+mg+Tablets/. 31 July 2017.
  40. Web site: mirtazapine (Rx) – Remeron, Remeron SolTab. Medscape. WebMD. 24 October 2013. 29 October 2013. https://web.archive.org/web/20131029200106/http://reference.medscape.com/drug/remeron-soltab-mirtazapine-342966. live.
  41. Web site: Australian Medicines Handbook . 2013 . Australian Medicines Handbook Pty Ltd . 5 October 2013 . 27 September 2011 . https://web.archive.org/web/20110927131220/http://www.amh.net.au/ . live .
  42. Book: British National Formulary (BNF) . 2013 . 65th . Pharmaceutical Press . 1120 . 978-0857110848 . registration .
  43. Web site: Remeron (Mirtazapine) Drug Information. RxList. 28 March 2016. 4 May 2017. https://web.archive.org/web/20170504234252/http://www.rxlist.com/remeron-drug/side-effects-interactions.htm. live.
  44. Hummel J, Westphal S, Weber-Hamann B, Gilles M, Lederbogen F, Angermeier T, Luley C, Deuschle M, Kopf D . 6 . Serum lipoproteins improve after successful pharmacologic antidepressant treatment: a randomized open-label prospective trial . The Journal of Clinical Psychiatry . 72 . 7 . 885–891 . July 2011 . 21294998 . 10.4088/JCP.09m05853blu .
  45. McIntyre RS, Soczynska JK, Konarski JZ, Kennedy SH . The effect of antidepressants on lipid homeostasis: a cardiac safety concern? . Expert Opinion on Drug Safety . 5 . 4 . 523–537 . July 2006 . 16774491 . 10.1517/14740338.5.4.523 . 23740352 .
  46. Möller HJ . Is there evidence for negative effects of antidepressants on suicidality in depressive patients? A systematic review . European Archives of Psychiatry and Clinical Neuroscience . 256 . 8 . 476–496 . December 2006 . 17143567 . 10.1007/s00406-006-0689-8 . 22708700 .
  47. Passier A, van Puijenbroek E . Mirtazapine-induced arthralgia . British Journal of Clinical Pharmacology . 60 . 5 . 570–572 . November 2005 . 16236049 . 1884949 . 10.1111/j.1365-2125.2005.02481.x .
  48. Abo-Zena RA, Bobek MB, Dweik RA . Hypertensive urgency induced by an interaction of mirtazapine and clonidine . Pharmacotherapy . 20 . 4 . 476–478 . April 2000 . 10772378 . 10.1592/phco.20.5.476.35061 . 9959199 .
  49. Natter J, Yokoyama T, Michel B . Relative frequency of drug-induced sleep disorders for 32 antidepressants in a large set of Internet user reviews . Sleep . 44 . 12 . zsab174 . December 2021 . 34252190 . 10.1093/sleep/zsab174 . free .
  50. Joseph RM, Jack RH, Morriss R, Knaggs RD, Butler D, Hollis C, Hippisley-Cox J, Coupland C . The risk of all-cause and cause-specific mortality in people prescribed mirtazapine: an active comparator cohort study using electronic health records . BMC Med . 20 . 1 . 43 . February 2022 . 35105363 . 8809032 . 10.1186/s12916-022-02247-x . free .
  51. Blier P . Pharmacology of rapid-onset antidepressant treatment strategies . The Journal of Clinical Psychiatry . 62 . Suppl 15 . 12–17 . 2001 . 11444761 .
  52. Vlaminck JJ, van Vliet IM, Zitman FG . [Withdrawal symptoms of antidepressants] . nl . Nederlands Tijdschrift voor Geneeskunde . 149 . 13 . 698–701 . March 2005 . 15819135 .
  53. Klesmer J, Sarcevic A, Fomari V . Panic attacks during discontinuation of mirtazepine . Canadian Journal of Psychiatry . 45 . 6 . 570–571 . August 2000 . 10986577 .
  54. MacCall C, Callender J . Mirtazapine withdrawal causing hypomania . The British Journal of Psychiatry . 175 . 4 . 390 . October 1999 . 10789310 . 10.1192/bjp.175.4.390a . free .
  55. Ali S, Milev R . Switch to mania upon discontinuation of antidepressants in patients with mood disorders: a review of the literature . Canadian Journal of Psychiatry . 48 . 4 . 258–264 . May 2003 . 12776393 . 10.1177/070674370304800410 . free .
  56. White N, Litovitz T, Clancy C . Suicidal antidepressant overdoses: a comparative analysis by antidepressant type . Journal of Medical Toxicology . 4 . 4 . 238–250 . December 2008 . 19031375 . 3550116 . 10.1007/bf03161207 .
  57. Nikolaou P, Dona A, Papoutsis I, Spiliopoulou C, Maravelias C . Death Due to Mirtazapine Overdose . 10.1080/15563650902952273 . Abstracts of the XXIX International Congress of the European Association of Poison Centres and Clinical Toxicologists, May 12–15, 2009, Stockholm, Sweden . 2009 . Clinical Toxicology . 47 . 5 . 436–510 . 218861198 . free .
  58. Book: Baselt RC . Disposition of Toxic Drugs and Chemicals in Man . 8th . Biomedical Publications . Foster City, CA . 2008 . 1045–7 . 978-0-9626523-7-0 .
  59. Buckley NA, McManus PR . Fatal toxicity of serotoninergic and other antidepressant drugs: analysis of United Kingdom mortality data . BMJ . 325 . 7376 . 1332–1333 . December 2002 . 12468481 . 137809 . 10.1136/bmj.325.7376.1332 .
  60. Book: Stahl SM . Stahl's Essential Psychopharmacology Online: Print and Online . Cambridge University Press . Cambridge, UK . 2008 . 978-0-521-74609-0 . 21 January 2012 . 19 June 2020 . https://web.archive.org/web/20200619204935/https://stahlonline.cambridge.org/prescribers_drug.jsf?page=0521683505c57_p325-330.html.therapeutics&name=Mirtazapine&title=Therapeutics . live .
  61. Silva J, Mota J, Azevedo P . California rocket fuel: And what about being a first line treatment? . European Psychiatry . March 2016 . 33 . S551 . 10.1016/j.eurpsy.2016.01.2033 . 75595266 .
  62. Wu CS, Tong SH, Ong CT, Sung SF . Serotonin Syndrome Induced by Combined Use of Mirtazapine and Olanzapine Complicated with Rhabdomyolysis, Acute Renal Failure, and Acute Pulmonary Edema-A Case Report . Acta Neurologica Taiwanica . 24 . 4 . 117–121 . December 2015 . 27333965 .
  63. Saguin E, Keou S, Ratnam C, Mennessier C, Delacour H, Lahutte B . Severe rhabdomyolysis induced by quetiapine and mirtazapine in a French military soldier . Journal of the Royal Army Medical Corps . 164 . 2 . 127–129 . May 2018 . 29632134 . 10.1136/jramc-2018-000939 . 4737517 .
  64. Houlihan DJ . Serotonin syndrome resulting from coadministration of tramadol, venlafaxine, and mirtazapine . The Annals of Pharmacotherapy . 38 . 3 . 411–413 . March 2004 . 14970364 . 10.1345/aph.1D344 . 33912489 .
  65. Anttila AK, Rasanen L, Leinonen EV . Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold . The Annals of Pharmacotherapy . 35 . 10 . 1221–1223 . October 2001 . 11675851 . 10.1345/aph.1A014 . 44807359 .
  66. Web site: Fluvoxamine and mirtazapine Interactions . 4 December 2022 . Drugs.com . 4 December 2022 . https://web.archive.org/web/20221204190716/https://www.drugs.com/drug-interactions/fluvoxamine-with-mirtazapine-1128-0-1640-0.html . live .
  67. Iqbal MM, Basil MJ, Kaplan J, Iqbal MT . Overview of serotonin syndrome . Annals of Clinical Psychiatry . 24 . 4 . 310–318 . November 2012 . 23145389 .
  68. Web site: Interactions Between Mirtazapine and Clonidine. 15 January 2021. 21 January 2021. https://web.archive.org/web/20210121041118/https://www.reliasmedia.com/articles/46173-interaction-between-mirtazapine-and-clonidine. live.
  69. Web site: PDSP Ki Database. Bryan Roth. Roth BL, Driscol J. Psychoactive Drug Screening Program (PDSP). University of North Carolina at Chapel Hill and the United States National Institute of Mental Health. 14 August 2017. 28 August 2021. https://web.archive.org/web/20210828173607/https://pdsp.unc.edu/databases/pdsp.php?receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=mirtazepine&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query. live.
  70. Tatsumi M, Groshan K, Blakely RD, Richelson E . Pharmacological profile of antidepressants and related compounds at human monoamine transporters . European Journal of Pharmacology . 340 . 2–3 . 249–258 . December 1997 . 9537821 . 10.1016/s0014-2999(97)01393-9 .
  71. Anttila SA, Leinonen EV . A review of the pharmacological and clinical profile of mirtazapine . CNS Drug Reviews . 7 . 3 . 249–264 . 2001 . 11607047 . 6494141 . 10.1111/j.1527-3458.2001.tb00198.x .
  72. Appl H, Holzammer T, Dove S, Haen E, Strasser A, Seifert R . Interactions of recombinant human histamine H1R, H2R, H3R, and H4R receptors with 34 antidepressants and antipsychotics . Naunyn-Schmiedeberg's Archives of Pharmacology . 385 . 2 . 145–170 . February 2012 . 22033803 . 10.1007/s00210-011-0704-0 . 14274150 .
  73. Van der Mey M, Windhorst AD, Klok RP, Herscheid JD, Kennis LE, Bischoff F, Bakker M, Langlois X, Heylen L, Jurzak M, Leysen JE . 6 . Synthesis and biodistribution of [11C]R107474, a new radiolabeled alpha2-adrenoceptor antagonist . Bioorganic & Medicinal Chemistry . 14 . 13 . 4526–4534 . July 2006 . 16517171 . 10.1016/j.bmc.2006.02.029 .
  74. de Boer TH, Maura G, Raiteri M, de Vos CJ, Wieringa J, Pinder RM . Neurochemical and autonomic pharmacological profiles of the 6-aza-analogue of mianserin, Org 3770 and its enantiomers . Neuropharmacology . 27 . 4 . 399–408 . April 1988 . 3419539 . 10.1016/0028-3908(88)90149-9 . 582691 .
  75. Gillman PK . Tricyclic antidepressant pharmacology and therapeutic drug interactions updated . British Journal of Pharmacology . 151 . 6 . 737–748 . July 2007 . 17471183 . 2014120 . 10.1038/sj.bjp.0707253 .
  76. Web site: Mirtazapine. Drugbank. 16 January 2020. 19 August 2020. https://web.archive.org/web/20200819113616/https://www.drugbank.ca/drugs/DB00370. live.
  77. Frazer A . Pharmacology of antidepressants . Journal of Clinical Psychopharmacology . 17 . Suppl 1 . 2S–18S . April 1997 . 9090573 . 10.1097/00004714-199704001-00002 .
  78. Fisar Z, Hroudová J, Raboch J . Inhibition of monoamine oxidase activity by antidepressants and mood stabilizers . Neuro Endocrinology Letters . 31 . 5 . 645–656 . 2010 . 21200377 .
  79. Richelson E . Pharmacology of antidepressants . Mayo Clinic Proceedings . 76 . 5 . 511–527 . May 2001 . 11357798 . 10.4065/76.5.511 . free .
  80. Book: Brunton L, Chabner BA, Knollman B . Goodman and Gilman's The Pharmacological Basis of Therapeutics, Twelfth Edition. 14 January 2011. McGraw Hill Professional. 978-0-07-176939-6. 410.
  81. Book: Schatzberg AF, Nemeroff CB. The American Psychiatric Association Publishing Textbook of Psychopharmacology. 10 May 2017. American Psychiatric Pub. 978-1-61537-122-8. 322–. 14 August 2017. 10 January 2023. https://web.archive.org/web/20230110194022/https://books.google.com/books?id=v9wnDwAAQBAJ&pg=PA322. live.
  82. Book: Brayfield A. Mirtazapine. Martindale: The Complete Drug Reference. The Royal Pharmaceutical Society of Great Britain. 3 November 2013. 30 January 2013. http://www.medicinescomplete.com/mc/martindale/current/11022-r.htm. 14 January 2021. https://web.archive.org/web/20210114165327/https://about.medicinescomplete.com/. live.
  83. Olianas MC, Dedoni S, Onali P . The atypical antidepressant mianserin exhibits agonist activity at κ-opioid receptors . British Journal of Pharmacology . 167 . 6 . 1329–1341 . November 2012 . 22708686 . 3504997 . 10.1111/j.1476-5381.2012.02078.x .
  84. De Boer T, Nefkens F, Van Helvoirt A . The alpha 2-adrenoceptor antagonist Org 3770 enhances serotonin transmission in vivo . European Journal of Pharmacology . 253 . 1–2 . R5–R6 . February 1994 . 7912194 . 10.1016/0014-2999(94)90778-1 .
  85. Berendsen HH, Broekkamp CL . Indirect in vivo 5-HT1A-agonistic effects of the new antidepressant mirtazapine . Psychopharmacology . 133 . 3 . 275–282 . October 1997 . 9361334 . 10.1007/s002130050402 . 230492 .
  86. Nakayama K, Sakurai T, Katsu H . Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation . Brain Research Bulletin . 63 . 3 . 237–241 . April 2004 . 15145142 . 10.1016/j.brainresbull.2004.02.007 . 14393829 .
  87. Blier P, Abbott FV . Putative mechanisms of action of antidepressant drugs in affective and anxiety disorders and pain . Journal of Psychiatry & Neuroscience . 26 . 1 . 37–43 . January 2001 . 11212592 . 1408043 . 20 June 2009 . dead . https://web.archive.org/web/20160306214237/https://www.cma.ca/multimedia/staticContent/HTML/N0/l2/jpn/vol-26/issue-1/pdf/pg37.pdf . 6 March 2016 .
  88. Millan MJ . Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies . Therapie . 60 . 5 . 441–460 . 2005 . 16433010 . 10.2515/therapie:2005065 .
  89. Dekeyne A, Millan MJ . Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization . Psychopharmacology . 203 . 2 . 329–341 . April 2009 . 18709360 . 10.1007/s00213-008-1259-8 . free .
  90. https://web.archive.org/web/20180109064133/https://pdfs.semanticscholar.org/4ab3/7aa1be6b898432f5faf5d5ff4a780e106a7b.pdf Mirtazapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation.
  91. Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F . 6 . Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram . The European Journal of Neuroscience . 12 . 3 . 1079–1095 . March 2000 . 10762339 . 10.1046/j.1460-9568.2000.00982.x . 23098292 . free .
  92. Fawcett J, Barkin RL . Review of the results from clinical studies on the efficacy, safety and tolerability of mirtazapine for the treatment of patients with major depression . Journal of Affective Disorders . 51 . 3 . 267–285 . December 1998 . 10333982 . 10.1016/S0165-0327(98)00224-9 .
  93. Graves SM, Napier TC . SB 206553, a putative 5-HT2C inverse agonist, attenuates methamphetamine-seeking in rats . BMC Neuroscience . 13 . 1 . 65 . June 2012 . 22697313 . 3441362 . 10.1186/1471-2202-13-65 . free .
  94. Colfax GN, Santos GM, Das M, Santos DM, Matheson T, Gasper J, Shoptaw S, Vittinghoff E . 6 . Mirtazapine to reduce methamphetamine use: a randomized controlled trial . Archives of General Psychiatry . 68 . 11 . 1168–1175 . November 2011 . 22065532 . 3437988 . 10.1001/archgenpsychiatry.2011.124 .
  95. Herrold AA, Shen F, Graham MP, Harper LK, Specio SE, Tedford CE, Napier TC . Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference . Drug and Alcohol Dependence . 99 . 1–3 . 231–239 . January 2009 . 18945553 . 10.1016/j.drugalcdep.2008.08.005 .
  96. Rose ME, Grant JE . Pharmacotherapy for methamphetamine dependence: a review of the pathophysiology of methamphetamine addiction and the theoretical basis and efficacy of pharmacotherapeutic interventions . Annals of Clinical Psychiatry . 20 . 3 . 145–155 . 2008 . 18633741 . 10.1080/10401230802177656 .
  97. Brackins T, Brahm NC, Kissack JC . Treatments for methamphetamine abuse: a literature review for the clinician . Journal of Pharmacy Practice . 24 . 6 . 541–550 . December 2011 . 22095579 . 10.1177/0897190011426557 . 37335642 .
  98. Brensilver M, Heinzerling KG, Shoptaw S . Pharmacotherapy of amphetamine-type stimulant dependence: an update . Drug and Alcohol Review . 32 . 5 . 449–460 . September 2013 . 23617468 . 4251965 . 10.1111/dar.12048 .
  99. Kast RE . Mirtazapine may be useful in treating nausea and insomnia of cancer chemotherapy . Supportive Care in Cancer . 9 . 6 . 469–470 . September 2001 . 11585276 . 10.1007/s005200000215 . 24132032 .
  100. Caldis EV, Gair RD . Mirtazapine for treatment of nausea induced by selective serotonin reuptake inhibitors . Canadian Journal of Psychiatry . 49 . 10 . 707 . October 2004 . 15560319 . 10.1177/070674370404901014 . free .
  101. Gillman PK . A systematic review of the serotonergic effects of mirtazapine in humans: implications for its dual action status . Human Psychopharmacology . 21 . 2 . 117–125 . March 2006 . 16342227 . 10.1002/hup.750 . 23442056 .
  102. Gillman PK . A review of serotonin toxicity data: implications for the mechanisms of antidepressant drug action . Biological Psychiatry . 59 . 11 . 1046–1051 . June 2006 . 16460699 . 10.1016/j.biopsych.2005.11.016 . 12179122 .
  103. Berling I, Isbister GK . Mirtazapine overdose is unlikely to cause major toxicity . Clinical Toxicology . 52 . 1 . 20–24 . January 2014 . 24228948 . 3894718 . 10.3109/15563650.2013.859264 .
  104. Freijo Guerrero J, Tardón Ruiz de Gauna L, Gómez JJ, Aguilera Celorrio L . [Serotonin syndrome after administration of mirtazapine in a critical care unit] . es . Revista Espanola de Anestesiologia y Reanimacion . 56 . 8 . 515–516 . October 2009 . 19994622 . 10.1016/s0034-9356(09)70444-x .
  105. Butler MC, Di Battista M, Warden M . Sertraline-induced serotonin syndrome followed by mirtazapine reaction . Progress in Neuro-Psychopharmacology & Biological Psychiatry . 34 . 6 . 1128–1129 . August 2010 . 20430060 . 10.1016/j.pnpbp.2010.04.015 . 20985498 .
  106. Decoutere L, De Winter S, Vander Weyden L, Spriet I, Schrooten M, Tournoy J, Fagard K . A venlafaxine and mirtazapine-induced serotonin syndrome confirmed by de- and re-challenge . International Journal of Clinical Pharmacy . 34 . 5 . 686–688 . October 2012 . 22752315 . 10.1007/s11096-012-9666-7 . 38692665 .
  107. Sato H, Ito C, Tashiro M, Hiraoka K, Shibuya K, Funaki Y, Iwata R, Matsuoka H, Yanai K . 6 . Histamine H1 receptor occupancy by the new-generation antidepressants fluvoxamine and mirtazapine: a positron emission tomography study in healthy volunteers . Psychopharmacology . 230 . 2 . 227–234 . November 2013 . 23728612 . 10.1007/s00213-013-3146-1 . 3052216 .
  108. Burrows GD, Kremer CM . Mirtazapine: clinical advantages in the treatment of depression . Journal of Clinical Psychopharmacology . 17 . Suppl 1 . 34S–39S . April 1997 . 9090576 . 10.1097/00004714-199704001-00005 .
  109. Zhu Y, Chen G, Zhang K, Chen C, Chen W, Zhu M, Jiang H . High-Throughput Metabolic Soft-Spot Identification in Liver Microsomes by LC/UV/MS: Application of a Single Variable Incubation Time Approach . Molecules . 27 . 22 . 8058 . November 2022 . 36432161 . 9693510 . 10.3390/molecules27228058 . free .
  110. Book: Al-Majed A, Bakheit AH, Alharbi RM, Abdel Aziz HA . Mirtazapine . Profiles of Drug Substances, Excipients and Related Methodology . 1 January 2018 . 43 . 209–254 . 10.1016/bs.podrm.2018.01.002 . 29678261 . 9780128151259 .
  111. Web site: Mirtazapine label – Australia. GuildLink, a wholly owned subsidiary company of the Pharmacy Guild of Australia.. 27 May 2016. 22 July 2017. 21 November 2018. https://web.archive.org/web/20181121120001/http://secure.healthlinks.net.au/content/msd/pi.cfm?product=mkpavant. dead.
  112. Kelder J, Funke C, De Boer T, Delbressine L, Leysen D, Nickolson V . A comparison of the physicochemical and biological properties of mirtazapine and mianserin . The Journal of Pharmacy and Pharmacology . 49 . 4 . 403–411 . April 1997 . 9232538 . 10.1111/j.2042-7158.1997.tb06814.x . 12270528 . free .
  113. 10.1080/00304940709458595. Improved Synthesis of Mirtazapine. Organic Preparations and Procedures International. 39. 4. 399–402. 2007. Srinivasa Rao DV, Dandala R, Handa VK, Sivakumaran M, Raghava Reddy AV, Naidu A . 98056931.
  114. Book: Schatzberg AF . Schatzberg AF, Nemeroff CB . The American Psychiatric Publishing Textbook of Psychopharmacology. 2009. American Psychiatric Pub.. Washington, D.C.. 9781585623099. 4th. Chapter 21: Mirtazapine.
  115. Kaspersen FM, Van Rooij FA, Sperling EG, Wieringa JH . The synthesis of org 3770 labelled with 3H, 13C AND 14C. Journal of Labelled Compounds and Radiopharmaceuticals. September 1989. 27. 9. 1055–1068. 10.1002/jlcr.2580270911.
  116. Web site: Remeron New FDA Drug Approvalh. Centerwatch. 26 August 2016. 5 August 2019. https://web.archive.org/web/20190805013642/https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/135/remeron-mirtazapine. live.
  117. Book: Index Nominum 2000: International Drug Directory. 2000. Taylor & Francis. 978-3-88763-075-1. 696–.
  118. Web site: Mirtazapine - Drugs.com. 14 August 2017. 17 November 2018. https://web.archive.org/web/20181117063153/https://www.drugs.com/international/mirtazapine.html. live.
  119. Book: Morton IK, Hall JM . Concise Dictionary of Pharmacological Agents: Properties and Synonyms. 6 December 2012. Springer Science & Business Media. 978-94-011-4439-1. 183.
  120. Kohler M, Bloch KE, Stradling JR . Pharmacological approaches to the treatment of obstructive sleep apnoea . Expert Opinion on Investigational Drugs . 18 . 5 . 647–656 . May 2009 . 19388881 . 10.1517/13543780902877674 . 57089477 . 23 December 2021 . 12 April 2022 . https://web.archive.org/web/20220412003252/https://www.zora.uzh.ch/id/eprint/28318/1/28318_manuscript.pdf . dead .
  121. Marshall NS, Yee BJ, Desai AV, Buchanan PR, Wong KK, Crompton R, Melehan KL, Zack N, Rao SG, Gendreau RM, Kranzler J, Grunstein RR . 6 . Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea . Sleep . 31 . 6 . 824–831 . June 2008 . 18548827 . 2442407 . 10.1093/sleep/31.6.824 .
  122. Masi G . Pharmacotherapy of pervasive developmental disorders in children and adolescents . CNS Drugs . 18 . 14 . 1031–1052 . 2004 . 15584771 . 10.2165/00023210-200418140-00006 . 25531695 .
  123. Marek GJ, Carpenter LL, McDougle CJ, Price LH . Synergistic action of 5-HT2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders . Neuropsychopharmacology . 28 . 2 . 402–412 . February 2003 . 12589395 . 10.1038/sj.npp.1300057 . free .
  124. Kumar R, Sachdev PS . Akathisia and second-generation antipsychotic drugs . Current Opinion in Psychiatry . 22 . 3 . 293–299 . May 2009 . 19378382 . 10.1097/YCO.0b013e32832a16da . 31506138 .
  125. Hieber R, Dellenbaugh T, Nelson LA . Role of mirtazapine in the treatment of antipsychotic-induced akathisia . The Annals of Pharmacotherapy . 42 . 6 . 841–846 . June 2008 . 18460588 . 10.1345/aph.1K672 . 19733585 .
  126. Graves SM, Rafeyan R, Watts J, Napier TC . Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside . Pharmacology & Therapeutics . 136 . 3 . 343–353 . December 2012 . 22960395 . 3483434 . 10.1016/j.pharmthera.2012.08.013 .
  127. Book: 9789400758056 . Polypharmacy in Psychiatry Practice, Volume I . Ritsner, MS . Ritsner MS . 2013 . Springer Science+Business Media Dordrecht . 10.1007/978-94-007-5805-6 . 7705779 .
  128. Vidal C, Reese C, Fischer BA, Chiapelli J, Himelhoch S . Meta-Analysis of Efficacy of Mirtazapine as an Adjunctive Treatment of Negative Symptoms in Schizophrenia . Clinical Schizophrenia & Related Psychoses . 9 . 2 . 88–95 . Jul 2015 . 23491969 . 10.3371/CSRP.VIRE.030813 .
  129. Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K . Mirtazapine improves visual hallucinations in Parkinson's disease: a case report . Psychogeriatrics . 13 . 2 . 103–107 . June 2013 . 23909968 . 10.1111/j.1479-8301.2012.00432.x . 1154368 . free .
  130. Eskeland S, Halvorsen JA, Tanum L . Antidepressants have Anti-inflammatory Effects that may be Relevant to Dermatology: A Systematic Review . Acta Dermato-Venereologica . 97 . 8 . 897–905 . August 2017 . 28512664 . 10.2340/00015555-2702 . free . 10852/63759 . free .
  131. Mirtazapine (Remeron). Vin.com. 8 August 2017. Gfeller R, Thomas M, Mayo I. 12 January 2013. 6 December 2010. https://web.archive.org/web/20101206073647/http://www.veterinarypartner.com/Content.plx?P=A. live.
  132. Agnew W, Korman R . Pharmacological appetite stimulation: rational choices in the inappetent cat . Journal of Feline Medicine and Surgery . 16 . 9 . 749–756 . September 2014 . 25146662 . 10.1177/1098612X14545273 . 37126352 . 11185246 .
  133. Web site: Mirataz EPAR . . 11 October 2019 . 12 July 2020 . 29 October 2020 . https://web.archive.org/web/20201029151621/https://www.ema.europa.eu/en/medicines/veterinary/EPAR/mirataz . live . Text was copied from this source, which is copyright European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged.
  134. Web site: Mirataz- mirtazapine ointment . DailyMed . 8 May 2020 . 12 July 2020 . 12 July 2020 . https://web.archive.org/web/20200712223906/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4a55914-6b6e-4e81-a84c-3999aa7bd79e . live .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mirtazapine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.